Dual Antiplatelet Therapy (DAPT) Versus Single Antiplatelet Therapy (SAPT) in Patients with Stroke Under 12 Hours: Meta-analysis and Systematic Review

Mohammad Jathy Oktariansyah* & Fifa Yuniarmi

Abstract

Background: Patients with ischemic stroke under 12 hours are typically treated with antiplatelet therapy. Combining two antiplatelet medicines agents with differing actions and antithrombotic efficacy increases the risk of hemorrhage. Among 1000 patients with ischemic stroke, dual-antiplatelet therapy was associated with 1 to 7 more ICH events than clopidogrel monotherapy and seemed to provide no significant additional benefit in reducing ischemic stroke events. Method: Search in PubMed, EMBASE, and the Cochrane Central Register about dual antiplatelet therapy versus monotherapy. The research method used was PRISMA guidelines followed by literature exclusions. The inclusion criteria in this literature search were medicinal, literature from 2013-2023. Results: There is 5 literatures discussing the advantages of DAPT with the results obtained DAPT was not associated with a significant reduction in recurrent ischemic stroke [pooled RR 0.79 (95%CI 0.67-0.92)] but was associated with a higher risk of major bleeding [pooled RR 1.86 (95%IC 1.86-3.32)]. Conclusion: Immediate administration of DAPT <12 hours after ischemic stroke can reduce recurrent stroke compared with antiplatelet monotherapy despite the increased risk of hemorrhage.

Keywords

antiplatelet; antithrombotic; dual antiplatelet therapy (DAPT); ischemic stroke; single antiplatelet therapy (SAPT)

Cite This Article

Oktariansyah, M. J., Yuniarmi, F. (2024). Dual Antiplatelet Therapy (DAPT) Versus Single Antiplatelet Therapy (SAPT) in Patients with Stroke Under 12 Hours: Meta-analysis and Systematic Review. International Journal of Scientific Advances (IJSCIA), Volume 5| Issue 1: Jan-Feb 2024, Pages 9-13, URL: https://www.ijscia.com/wp-content/uploads/2024/01/Volume5-Issue1-Jan-Feb-No.542-9-13.pdf

Volume 5 | Issue 1: Jan-Feb 2024